[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.119.171. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 960
Citations 0
Comment & Response
November 24, 2015

Cost-effectiveness of Statin Therapy for ASCVD

Author Affiliations
  • 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA. 2015;314(20):2191. doi:10.1001/jama.2015.12919

To the Editor Using a microsimulation model, Dr Pandya and colleagues1 found that it was cost-effective to treat more than 60% of all US adults aged 40 through 75 years with a generic statin for primary prevention of atherosclerotic cardiovascular disease (ASCVD). Using a weighted average of the lowest Red Book wholesale acquisition costs for generic 20-mg tablets, the authors estimated costs of $11 per patient per year for simvastatin, $110 for atorvastatin, and $2277 for rosuvastatin in the base-case analysis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×